首页> 外文期刊>Journal of Cardiovascular and Thoracic Research >Comparison of apolipoprotein-A1 levels between paroxysmal atrial fibrillation patients and healthy subjects
【24h】

Comparison of apolipoprotein-A1 levels between paroxysmal atrial fibrillation patients and healthy subjects

机译:阵发性心房颤动患者与健康受试者的载脂蛋白-A1水平的比较

获取原文
       

摘要

Introduction: Studies found that the inflammation plays a key role in the pathogenesis of paroxysmal atrial fibrillation (PAF). It is well-known that apolipoprotein-A1 (Apo-A1) demonstrates antiinflammatory and anti-oxidant properties in a healthy physiological system. In the present study, we aimed to determine whether there is any difference of Apo-A1 levels in patients with PAF and healthy subjects. Methods: In this prospective cohort study, we enrolled a total of 35 PAF patients and 34 comparable healthy participants. Apo-A1 levels were measured from each subject using an immunophelometric method. All enrolled subjects were followed-up for one year during the study period. Results: Serum high-sensitivity C-reactive protein (hs-CRP) levels were statistically higher in PAF patients compared to healthy subjects (1.54±1.99 vs. 1.06±2.01, P= 0.016, respectively). Of note, patients with PAF had lower Apo-A1 levels (1.84±0.74 vs. 2.55±0.44, P= 0.001, respectively). There was no statistical difference between the groups in terms of apolipoprotein-B levels (1.08±0.36 vs. 0.99±0.38, P= 0.339, respectively). We did not find any correlation between Apo-A1 levels and PAF attacks in the study. Conclusion: The main finding of this study was that Apo-A1 levels were significantly lower in PAF patients compared to healthy participants. Based on our results, we considered that Apo-A1 may have a key role in the pathogenesis of PAF.
机译:介绍:研究发现,炎症在阵发性心房颤动(PAF)的发病机制中起着关键作用。众所周知,载脂蛋白-A1(APO-A1)在健康的生理系统中证明抗炎和抗氧化剂性能。在本研究中,我们旨在确定PAF和健康受试者患者APO-A1水平是否有任何差异。方法:在这项未来的队列研究中,我们共招收了35名PAF患者和34名可比健康的参与者。使用免疫蛋糕方法从每个受试者测量APO-A1水平。在研究期间,所有注册的科目都随访一年。结果:PAF患者血清高敏感性C-反应蛋白(HS-CRP)水平与健康受试者相比,PAF患者统计学较高(1.54±1.99与1.06±2.01,P = 0.016)。注意,PAF患者的APO-A1水平降低(1.84±0.74,分别为2.55±0.44,P = 0.001)。在载脂蛋白-B水平方面没有统计学差异(1.08±0.36,分别为0.99±0.38,P = 0.339)。我们在研究中没有发现APO-A1级别和PAF攻击之间的任何相关性。结论:本研究的主要发现是PAF患者的APO-A1水平与健康参与者相比,PAF患者显着降低。根据我们的结果,我们认为APO-A1可能在PAF的发病机制中具有关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号